Evidence map›Paper›PMID 33665638›Full record

ArticleCell reports. Medicine2021

Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients.

Lili Aslostovar, Allison L Boyd, Yannick D Benoit, Justin Di Lu, Juan Luis Garcia Rodriguez, Mio Nakanishi, Deanna P Porras, Jennifer C Reid, Ryan R Mitchell, Brian Leber and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Lili AslostovarStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Allison L BoydStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Yannick D BenoitDepartment of Cellular and Molecular Medicine, Ottawa University, Ottawa, ON, Canada.
Justin Di LuDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
Juan Luis Garcia RodriguezStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Mio NakanishiStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Deanna P PorrasStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Jennifer C ReidStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Ryan R MitchellStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Brian LeberDepartment of Medicine, McMaster University, Juravinski Hospital, Hamilton, ON, Canada.
Anargyros XenocostasDivision of Hematology, Department of Medicine, University of Western Ontario, London Health Sciences Centre, London, ON, Canada.
Ronan FoleyDepartment of Pathology and Molecular Medicine, McMaster University, Juravinski Hospital, Hamilton, ON, Canada.
Mickie BhatiaStem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
Population Health Research Institute · CAMcMaster University · CAJuravinski Hospital · CALondon Health Sciences Centre · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aberrant expression of dopamine receptors (DRDs) in acute myeloid leukemia (AML) cells has encouraged the repurposing of DRD antagonists such as thioridazine (TDZ) as anti-leukemic agents. Here, we access patient cells from a Phase I dose escalation trial to resolve the cellular and molecular bases of response to TDZ, and we extend these findings to an additional independent cohort of AML patient samples tested preclinically. We reveal that in DRD2

Indexed as

HematopoiesisHumansLeukemia, Myeloid, AcuteNeoplastic Stem CellsReceptors, DopamineSignal TransductionThioridazineReceptors, DopamineThioridazineacute myeloid leukemiacyclic AMPdopamine receptorleukemic progenitorPhase I trialQTc intervaltargeted therapythioridazinexenograft

Identifiers

PMID33665638
PMCPMC7897800
OpenAlexW3130559842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.